Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.69 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CA7 | P43166 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA4 | P22748 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.48 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.48 |
| ▸ | BCHE | P06276 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL585111 | 0.89 | IDO1 (0.62) | IDO1TAAR1CHRM2CHRM1CA1 | |
| SCHEMBL29364891 | 0.89 | IDO1 (0.62) | IDO1TAAR1CHRM2CHRM1CA1 | |
| SCHEMBL16269056 | 0.89 | IDO1 (0.62) | IDO1TAAR1CHRM2CHRM1CA1 | |
| SCHEMBL3166142 | 0.87 | IDO1 (0.60) | IDO1TAAR1CHRM2CHRM1CA1 | |
| SCHEMBL28384840 | 0.87 | IDO1 (0.66) | IDO1TAAR1CHRM2CHRM1CA1 | |
| SCHEMBL4661995 | 0.87 | IDO1 (0.60) | IDO1TAAR1CHRM2CHRM1CA1 | |
| SCHEMBL31048 | 0.86 | IDO1 (0.69) | IDO1TAAR1CHRM2CHRM1CA1 | |
| SCHEMBL10607688 | 0.86 | IDO1 (0.69) | IDO1TAAR1CHRM2CHRM1CA1 | |
| SCHEMBL31290863 | 0.86 | IDO1 (0.69) | IDO1TAAR1CHRM2CHRM1CA1 | |
| SCHEMBL17230506 | 0.86 | IDO1 (0.58) | IDO1TAAR1CHRM2CHRM1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 616 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240141362-A1 | MODIFIED OLIGONUCLEOTIDES WITH INCREASED STABILITY | UNIV MASSACHUSETTS (US) | 2024-05-02 | — | — | US | claimed |
| US-11820985-B2 | Modified oligonucleotides with increased stability | UNIVERSITY OF MASSACHUSETTS (US) | 2023-11-21 | — | — | US | claimed |
| EP-4203940-A1 | METHODS TO PRODUCE VERY LONG CHAIN FATTY ACIDS (VLCFA) | The United States Of America, As Represented By The Secretary, Department of Health and Human Services (US) | 2023-07-05 | — | — | EP | claimed |
| EP-3946369-A2 | MODIFIED OLIGONUCLEOTIDES WITH INCREASED STABILITY | University Of Massachusetts (US) | 2022-02-09 | — | — | EP | claimed |
| CN-112175265-A | Modified color master batch and preparation method thereof | 方少山 | 2021-01-05 | — | — | CN | claimed |
| US-20200385740-A1 | MODIFIED OLIGONUCLEOTIDES WITH INCREASED STABILITY | UNIVERSITY OF MASSACHUSETTS | 2020-12-10 | — | — | US | claimed |
| EP-3746509-A1 | BUGPHOBIC AND ICEPHOBIC COMPOSITIONS WITH FLUID ADDITIVES | HRL Laboratories, LLC (US) | 2020-12-09 | — | — | EP | claimed |
| WO-2020198509-A2 | MODIFIED OLIGONUCLEOTIDES WITH INCREASED STABILITY | UNIVERSITY OF MASSACHUSETTS (US) | 2020-10-01 | — | — | WO | claimed |
| US-20200079718-A1 | Menaquinol Compositions and Methods of Treatment | Epizon Pharma, Inc. (US) | 2020-03-12 | — | — | US | claimed |
| CN-106573904-B | Method for generating beraprost and its derivative | 朗格生物技术公共公益股份有限公司 | 2019-11-08 | — | — | CN | claimed |
| EP-1893571-A2 | PROCESS FOR PRODUCTION OF 4-BIPHENYLYAZETIDIN-2-ONES | Microbia Inc. (US) | 2008-03-05 | — | — | EP | claimed |
| EP-1885703-A2 | PROCESSES FOR PRODUCTION OF PHENOLIC 4-BIPHENYLYLAZETIDIN-2-ONES | Microbia, Inc. (US) | 2008-02-13 | — | — | EP | claimed |
| CN-100355772-C | Steroid compound with 5-alpha reductase active and preparation process thereof | UNIV TIANJIN (CN) | 2007-12-19 | — | — | CN | claimed |
| WO-2006127893-A2 | PROCESSES FOR PRODUCTION OF 4-(BIPHENYLYL)AZETIDIN-2-ONE PHOSPHONIC ACIDS | MICROBIA, INC. (US) | 2006-11-30 | — | — | WO | claimed |
| WO-2006122020-A2 | PROCESS FOR PRODUCTION OF 4-BIPHENYLYAZETIDIN-2-ONES | MICROBIA, INC. (US) | 2006-11-16 | — | — | WO | claimed |
| WO-2006122216-A2 | PROCESSES FOR PRODUCTION OF PHENOLIC 4-BIPHENYLYLAZETIDIN-2-ONES | MICROBIA, INC. (US) | 2006-11-16 | — | — | WO | claimed |
| CN-1793164-A | Steroid compound with 5-alpha reductase active and preparation process thereof | UNIV TIANJIN (CN) | 2006-06-28 | — | — | CN | claimed |
| EP-0781293-A4 | COMPOSITIONS FOR ENZYME CATALYZED TEMPLATE-INDEPENDENT CREATION OF PHOSPHODIESTER BONDS USING PROTECTED NUCLEOTIDES | HIATT ANDREW C ROSE HIATT BIOT (US) | 1999-05-26 | — | — | EP | claimed |
| EP-0781293-A1 | COMPOSITIONS FOR ENZYME CATALYZED TEMPLATE-INDEPENDENT CREATION OF PHOSPHODIESTER BONDS USING PROTECTED NUCLEOTIDES | Hiatt, Andrew C. (US) | 1997-07-02 | — | — | EP | claimed |
| WO-1996007669-A1 | COMPOSITIONS FOR ENZYME CATALYZED TEMPLATE-INDEPENDENT CREATION OF PHOSPHODIESTER BONDS USING PROTECTED NUCLEOTIDES | ROSE-HIATT BIOTECHNOLOGY PARTNERSHIP (US) | 1996-03-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200079718-A1 | Menaquinol Compositions and Methods of Treatment | SDHA, SDHB, NDUFB7 | IDO1 3891/4885TAAR1 4422/4885CHRM2 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.